Mechanisms of natural tolerance in the intestine: Implications for inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 10, Issue 4, 2004, Pages 462-478

  Jump, Robin L ^a   Levine, Alan D ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive immunity; Commensal flora; Crohn's disease; Innate immunity; Intestinal epithelial cell; Lymphocyte; Review; Tolerance; Ulcerative colitis

Indexed keywords

CASPASE RECRUITMENT DOMAIN PROTEIN 15; CYCLOOXYGENASE 2 INHIBITOR; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; PROBIOTIC AGENT; TOLL LIKE RECEPTOR;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; COMMENSALISM; DISEASE EXACERBATION; ENTERITIS; HOMEOSTASIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSTIMULATION; INTESTINE; INTESTINE FLORA; INTESTINE MUCOSA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTAKE; REVIEW;

ADAPTATION, PHYSIOLOGICAL; BACTERIA; HUMANS; IMMUNE SYSTEM; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; PROTEINS; SELF TOLERANCE;

EID: 3543093971     PISSN: 10780998     EISSN: None     Source Type: Journal    
DOI: 10.1097/00054725-200407000-00023     Document Type: Review

References (202)

1. Wardrop RM 3rd, Whitacre CC. Oral tolerance in the treatment of inflammatory autoimmune diseases. Inflamm Res. 1999;48:106-119.
2. Dakin R. Remarks on a cutaneous affection produced by certain poisonous vegetables. Am J Med Sci. 1829;4:98-100.
3. Strobel S, Mowat AM. Immune responses to dietary antigens: oral tolerance, Immunol Today. 1998;19:173-181.
4. Wells HG, Osborne TB. The biological reactions of the vegetable proteins. I. Anaphylaxis. J Infect Dis. 1911;8:66-124.
5. Challacombe SJ, Tomasi TB Jr. Systemic tolerance and secretory immunity after oral immunization, J Exp Med. 1980;152:1459-1472.
6. Garside P, Mowat AM, Khoruts A. Oral tolerance in disease. Gut. 1999; 44:137-142.
7. Dresser DW. Effectiveness of lipd and lipidophilic substances as adjuvants. Nature. 1961;191:1169-1171.
8. Ria F, Chan BM, Scherer MT, et al. Immunological activity of covalently linked T-cell epitopes. Nature. 1990;343:381-383.
9. Switzer SK, Wallner BP, Briner TJ, et al. Bolus injection of aqueous antigen leads to a high density of T-cell- receptor ligand in the spleen, transient T-cell activation and anergy induction. Immunology. 1998;94: 513-522.
10. Chen Y, Inobe J, Marks R, et al. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature. 1995;376:177-180.
11. Mowat AM, Steel M, Worthey EA, et al. Inactivation of Th1 and Th2 cells by feeding ovalbumin. Ann N Y Acad Sci. 1996;778:122-132.
12. de St Groth BF. DCs and peripheral T cell tolerance. Semin Immunol. 2001;13:311-322.
13. Lanoue A, Bona C, von Boehmer H, et al. Conditions that induce tolerance in mature CD4+ T cells. J Exp Med. 1997;185:405-414.
14. Renz H, Herz U. Immune mechanisms of peripheral tolerance. Nutrition Research. 1998;18:1327-1333.
15. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N Engl J Med. 2001;344:655-664.
16. Thorstenson KM, Khoruts A. Generation of anergic and potentially immunoregulatory CD25+CD4 T cells in vivo after induction of peripheral tolerance with intravenous or oral antigen, J Immunol. 2001;167:188-195.
17. Fujihashi K, Kweon MN, Kiyono H, et al. A T cell/B cell/epithelial cell internet for mucosal inflammation and immunity. Springer Semin Immunopathol 1997;18:477-494.
18. Kweon MN, Fujihashi K, VanCott JL, et al. Lack of orally induced systemic unresponsiveness in IFN-gamma knockout mice. J Immunol. 1998;160:1687-1693.
19. Tsitoura DC, DeKruyff RH, Lamb JR, et al. Intranasal exposure to protein antigen induces immunological tolerance mediated by functionally disabled CD4+ T cells. J Immunol. 1999;163:2592-2600.
20. Hoyne GF, Tan K, Corsin-Jimenez M, et al. Immunological tolerance to inhaled antigen. Am J Respir Crit Care Med. 2000;162:S169-S174.
21. Black CA, Rohan LC, Cost M, et al. Vaginal mucosa serves as an inductive site for tolerance. J Immunol. 2000;165:5077-5083.
22. Iijima H, Takahashi I, Kiyono H. Mucosal immune network in the gut for the control of infectious diseases. Rev Med Virol. 2001;11:117-133.
23. Garside P, Mowat AM. Oral tolerance. Semin Immunol. 2001;13:177-185.
24. Norin KE, Gustafsson BE, Lindblad BS, et al. The establishment of some microflora associated biochemical characteristics in feces from children during the first years of life. Acta Paediatr Scand. 1985;74:207-212.
25. Abrams GD, Bauer H, Sprinz H. Influence of the normal flora on mucosal morphology and cellular renewal in the ileum. A comparison of germ-free and conventional mice. Lab Invest. 1963;12:355-364.
26. Wannemuehler MJ, Kiyono H, Babb JL, et al. Lipopolysaccharide (LPS) regulation of the immune response: LPS converts germfree mice to sensitivity to oral tolerance induction, J Immunol. 1982;129:959-965.
27. Moreau M, Richards JC, Perry MB, et al. Structural analysis of the specific capsular polysaccharide of Streptococcus pneumoniae type 45 (American type 72). Biochemistry (Mosc). 1988;27:6820-6829.
28. Berg RD. The indigenous gastrointestinal microflora. Trends Microbiol. 1996;4:430-435.
29. Sudo N, Sawamura S, Tanaka K, et al. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction, J Immunol. 1997;159:1739-1745.
30. Tannock GW. Influences of the normal microbiota on the animal host. In: Mackie RI, and Isaacson, RE, eds. Gastrointestinal Microbiology. New York: Chapman & Hall; 1997:466-497.
31. Hooper LV, Wong MH, Thelin A, et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science. 2001;291:881-884.
32. Foo MC, Lee A. Antigenic cross-reaction between mouse intestine and a member of the autochthonous microflora, Infect Immun. 1974;9:1066-1069.
33. Savage DC. Microbial ecology of the gastrointestinal tract. Annu Rev Microbiol. 1977;31:107-133.
34. van der Waaij D. The ecology of the human intestine and its consequences for overgrowth by pathogens such as Clostridium difficile. Annu Rev Microbiol. 1989;43:69-87.
35. Duchmann R, Neurath MF, Meyer zum Buschenfelde KH. Responses to self and non-self intestinal microflora in health and inflammatory bowel disease. Res Immunol. 1997;148:589-594.
36. Duchmann R, Kaiser I, Hermann E, et al. Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD). Clin Exp Immunol. 1995;102:448-455.
37. Duchmann R, Schmitt E, Knolle P, et al. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur J Immunol. 1996;26:934-938.
38. Jakob B, Birkholz S, Schneider T, et al. Immune response to autologous and heterologous Helicobacter pylori antigens in humans. Microsc Res Tech. 2001;53:419-424.
39. Duchmann R, May E, Heike M, et al. T cell specificity and cross reactivity towards enterobacteria, bacteroides, bifidobacterium, and antigens from resident intestinal flora in humans. Gut. 1999;44:812-818.
40. Matzinger P. Essay 1: the Danger model in its historical context. Scand J Immunol. 2001;54:4-9.
41. van der Waaij D, Vossen JM, Altes CK, et al. Reconventionalization following antibiotic decontamination in man and animals. Am J Clin Nutr. 1977;30:1887-1895.
42. Conway PL. Development of Intestinal Microbiota. In: Mackie RI, White BA, Isaacson RE, eds. Gastrointestinal Microbiology. New York: Chapman and Hall; 1997:3-38.
43. Dunne C. Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm Bowel Dis. 2001;7:136-145.
44. Wakeland EK, Liu K, Graham RR, et al. Delineating the genetic basis of systemic lupus erythematosus. Immunity. 2001;15:397-408.
45. Kho YH, Pool MO, Jansman FG, et al. Pharmacotherapeutic options in inflammatory bowel disease: an update. Pharm World Sci. 2001;23: 17-21.
46. Ahmad T, Satsangi J, McGovern D, et al. Review article: the genetics of inflammatory bowel disease. Aliment Pharmacol Ther. 2001;15:731-748.
47. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001;358:903-911.
48. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet. 2001;358:221-229.
49. Robson MG, Walport MJ. Pathogenesis of systemic lupus erythematosus (SLE). Clin Exp Allergy. 2001;31:678-685.
50. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411: 603-606.
51. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001; 411:599-603.
52. Todd JA. Human genetics. Tackling common disease. Nature 2001;411: 537-539.
53. Hampe J, Frenzel H, Mirza MM, et al. Evidence for a NOD2-independent susceptibility locus for inflammatory bowel disease on chromosome 16p. Proc Natl Acad Sci U S A. 2002;99:321-326.
54. Fujinami RS. Can virus infections trigger autoimmune disease? J Autoimmun. 2001;16:229-234.
55. Toivanen P. From reactive arthritis to rheumatoid arthritis. J Autoimmun. 2001;16:369-371.
56. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292:1115-1118.
57. Hecht G. Innate mechanisms of epithelial host defense: spotlight on intestine. Am J Physiol. 1999;277:C351-C358.
58. Van Houte J, Gibbons RJ. Studies of the cultivable flora of normal human feces. Antonie Van Leeuwenhoek. 1966;32:212-222.
59. Moore WE, Holdeman LV. Human fecal flora: the normal flora of 20 Japanese-Hawaiians. Appl Microbiol. 1974;27:961-979.
60. Macpherson AJ, Maloy KJ, Bjarnason I. Intolerance of the dirty intestine. Gut. 1999;44:774-775.
61. Jung HC, Eckmann L, Yang SK, et al. A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion. J Clin Invest. 1995;95:55-65.
62. Kato T, Owen RL. Structure and function of intestinal mucosal epithelium. In: Ogra PL, Mestecky J, Lamm M, Strober W, Bienenstock J, McGhee J, eds. Mucosal Immunology, 2nd ed. New York: Academic Press; 1999:1628.
63. Sprinz H. Morphologcal response of intestinal mucosa to enteric bacteria and its implications for sprue and Asiatic cholera. Fed Proc. 1962;21:57.
64. Pollard M, Sharon H. Responses of the Peyer's patches in germ-free mice to antigenic stimulation, Infect Immun. 1970;2:96-100.
65. Wostmann BS, Larkin C, Moriarty A, et al. Dietary intake, energy metabolism, and excretory losses of adult male germfree Wistar rats. Lab Anim Sci. 1983;33:46-50.
66. Abrams GD, Bishop JE. Effect of the normal microbial flora on gastrointestinal motility. Proc Soc Exp Biol Med. 1967;126:301-304.
67. Husebye E, Hellstrom PM, Midtvedt T. Intestinal microflora stimulates myoelectric activity of rat small intestine by promoting cyclic initiation and aboral propagation of migrating myoelectric complex. Dig Dis Sci. 1994;39:946-956.
68. Umesaki Y, Okada Y, Matsumoto S, et al. Segmented filamentous bacteria are indigenous intestinal bacteria that activate intraepithelial lymphocytes and induce MHC class II molecules and fucosyl asialo GM1 glycolipids on the small intestinal epithelial cells in the ex-germ-free mouse. Microbiol Immunol. 1995;39:555-562.
69. Umesaki Y, Setoyama H, Matsumoto S, et al. Differential roles of segmented filamentous bacteria and clostridia in development of the intestinal immune system. Infect Immun. 1999;67:3504-3511.
70. Jiang HQ, Bos NA, Cebra JJ. Timing, localization, and persistence of colonization by segmented filamentous bacteria in the neonatal mouse gut depend on immune status of mothers and pups. Infect Immun. 2001; 69:3611-3617.
71. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB- alpha ubiquitination. Science. 2000; 289:1560-1563.
72. Berg RD, Savage DC. Immune responses of specific pathogen-free and gnotobiotic mice to antigens of indigenous and nonindigenous microorganisms. Infect Immun. 1975;11:320-329.
73. Foo MC, Lee A. Immunological response of mice to members of the autochthonous intestinal microflora. Infect Immun. 1972;6:525-532.
74. MacDonald TT, Carter PB. Requirement for a bacterial flora before mice generate cells capable of mediating the delayed hypersensitivity reaction to sheep red blood cells. J Immunol. 1979;122:2624-2629.
75. Dubos R. Staphylococci and Infection Immunity. Am J Dis Children. 1963;105:643-645.
76. Freter R. Experimental enteric Shigella and Vibrio infections in mice and guinea pigs. J Exp Med. 1956;104:411.
77. Bernet MF, Brassart D, Neeser JR, et al. Adhesion of human bifidobacterial strains to cultured human intestinal epithelial cells and inhibition of enteropathogen-cell interactions. Appl Environ Microbiol. 1993;59: 4121-4128.
78. Saavedra JM, Bauman NA, Oung I, et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet. 1994;344:1046-1049.
79. Mack DR, Michail S, Wei S, et al. Probiotics inhibit enteropathogenic E. coli adherence in vitro by inducing intestinal mucin gene expression. Am J Physiol. 1999;276:G941-G950.
80. Ayabe T, Satchell DP, Wilson CL, et al. Secretion of microbicidal alpha-defensins by intestinal Paneth cells in response to bacteria. Nat Immunol. 2000;1:113-118.
81. Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science. 1999;286:113-117.
82. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun. 2000;68:7010-7017.
83. Abreu MT, Vora P, Faure E, et al. Decreased expression of Toll-like receptor-4 and MD-2 correlates with intestinal epithelial cell protection against dysregulated proinflammatory gene expression in response to bacterial lipopolysaccharide. J Immunol. 2001;167:1609-1616.
84. Cario E, Rosenberg IM, Brandwein SL, et al. Lipopolysaccharide activates distinct signaling pathways in intestinal epithelial cell lines expressing Toll-like receptors. J Immunol. 2000;164:966-972.
85. Gewirtz AT, Navas TA, Lyons S, et al. Cutting edge: bacterial flagellin activates basolaterally expressed TLR5 to induce epithelial proinflammatory gene expression. J Immunol. 2001;167:1882-1885.
86. Bland PW, Warren LG. Antigen presentation by epithelial cells of the rat small intestine. II. Selective induction of suppressor T cells. Immunology. 1986;58:9-14.
87. Kaiserlian D, Vidal K, Revillard JP. Murine enterocytes can present soluble antigen to specific class II- restricted CD4+ T cells. Eur J Immunol. 1989;19:1513-1516.
88. Hoyne GF, Callow MG, Kuo MC, et al. Presentation of peptides and proteins by intestinal epithelial cells. Immunology. 1993;80:204-208.
89. Hershberg RM, Cho DH, Youakim A, et al. Highly polarized HLA class II antigen processing and presentation by human intestinal epithelial cells. J Clin Invest. 1998;102:792-803.
90. Mayrhofer G. Absorption and presentation of antigens by epithelial cells of the small intestine: hypotheses and predictions relating to the pathogenesis of coeliac disease. Immunol Cell Biol. 1995;73:433-439.
91. Hershberg RM, Blumberg RS. What's so (Co)stimulating about the intestinal epithelium? Gastroenterology. 1999;117:726-728.
92. Hershberg RM, Mayer LF. Antigen processing and presentation by intestinal epithelial cells - polarity and complexity. Immunol Today. 2000; 21:123-128.
93. Karlsson M, Lundin S, Dahlgren U, et al. Tolerosomes' are produced by intestinal epithelial cells. Eur J Immunol. 2001;31:2892-2900.
94. Mayer L, Shlien R. Evidence for function of Ia molecules on gut epithelial cells in man. J Exp Med. 1987;166:1471-1483.
95. Mayer L. Regulation of mucosal immune responses: distinct antigens and antigen presenting cells. J Clin Immunol. 1997;17:349-353.
96. Mayer L. Current concepts in mucosal immunity. I. Antigen presentation in the intestine: new rules and regulations. Am J Physiol. 1998;274: G7-G9.
97. Morteau O. COX-2: promoting tolerance. Nat Med. 1999;5:867-868.
98. Newberry RD, Stenson WF, Lorenz RG. Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. Nat Med. 1999;5:900-906.
99. Newberry RD, McDonough JS, Stenson WF, et al. Spontaneous and continuous cyclooxygenase-2-dependent prostaglandin E2 production by stromal cells in the murine small intestine lamina propria: directing the tone of the intestinal immune response. J Immunol. 2001;166:4465-4472.
100. Berg DJ, Zhang J, Lauricella DM, et al. IL-10 is a central regulator of cyclooxygenase-2 expression and prostaglandin production. J Immunol. 2001;166:2674-2680.
101. Smith PD, Janoff EN, Mosteller-Barnum M, et al. Isolation and purification of CD14-negative mucosal macrophages from normal human small intestine. J Immunol Methods. 1997;202:1-11.
102. Smith PD, Smythies LE, Mosteller-Barnum M, et al. Intestinal macrophages lack CD14 and CD89 and consequently are down- regulated for LPS- and IgA-mediated activities. J Immunol. 2001;167:2651-2656.
103. Qiao L, Braunstein J, Golling M, et al. Differential regulation of human T cell responsiveness by mucosal versus blood monocytes. Eur J Immunol. 1996;26:922-927.
104. Heystek HC, Moulon C, Woltman AM, et al. Human immature dendritic cells efficiently bind and take up secretory IgA without the induction of maturation. J Immunol. 2002;168:102-107.
105. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233-238.
106. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000;192:1213-1222.
107. Viney JL, Mowat AM, O'Malley JM, et al. Expanding dendritic cells in vivo enhances the induction of oral tolerance. J Immunol. 1998;160: 5815-5825.
108. Everson MP, McDuffie DS, Lemak DG, et al. Dendritic cells from different tissues induce production of different T cell cytokine profiles. J Leukoc Biol. 1996;59:494-498.
109. Harper HM, Cochrane L, Williams NA. The role of small intestinal antigen-presenting cells in the induction of T-cell reactivity to soluble protein antigens: association between aberrant presentation in the lamina propria and oral tolerance. Immunology. 1996;89:449-456.
110. Iwasaki A, Kelsall BL. Freshly isolated Peyer's patch, but not spleen, dendritic cells produce interleukin 10 and induce the differentiation of T helper type 2 cells. J Exp Med. 1999;190:229-239.
111. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389: 737-742.
112. Weiner HL, Friedman A, Miller A, et al. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol. 1994;12:809-837.
113. Shanahan F. Nutrient tasting and signaling mechanisms in the gut V. Mechanisms of immunologic sensation of intestinal contents. Am J Physiol Gastrointest Liver Physiol. 2000;278:G19l-G196.
114. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science. 1996;272:60-66.
115. Brandtzaeg P, Farstad IN, Haraldsen G. Regional specialization in the mucosal immune system: primed cells do not always home along the same track. Immunol Today. 1999;20:267-277.
116. Husband AJ. Role of gram negative bacteria in ontogeny of gut immunity. Aust J Exp Biol Med Sci. 1980;58:297-299.
117. Gaskins HR. Immunological aspects of host/microbiota interactions at the intestinal epithelium. In: Mackie RI, White BA, Isaacson RE, eds. Gastrointestinal Microbiology. New York: Chappman & Hall; 1997:537-587.
118. Kramer DR, Cebra JJ. Early appearance of "natural" mucosal IgA responses and germinal centers in suckling mice developing in the absence of maternal antibodies. J Immunol. 1995;154:2051-2062.
119. Mestecky J, Russell MW, Elson CO. Intestinal IgA: novel views on its function in the defence of the largest mucosal surface. Gut. 1999;44:2-5.
120. Shroff KE, Meslin K, Cebra JJ. Commensal enteric bacteria engender a self-limiting humoral mucosal immune response while permanently colonizing the gut. Infect Immun. 1995;63:3904-3913.
121. Lamm ME. Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol. 1997;51:311-340.
122. Macpherson AJ, Hunziker L, McCoy K, et al. IgA responses in the intestinal mucosa against pathogenic and non- pathogenic microorganisms. Microbes Infect. 2001;3:1021-1035.
123. Macpherson AJ, Gatto D, Sainsbury E, et al. A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria. Science. 2000;288:2222-2226.
124. Freter R. Parameters affecting the association of vibrios with the intestinal surface in experimental cholera. Infect Immun. 1972;6:134-141.
125. Russell MW, Reinholdt J, Kilian M. Anti-inflammatory activity of human IgA antibodies and their Fab alpha fragments: inhibition of IgG-mediated complement activation. Eur J Immunol. 1989;19:2243-2249.
126. Alpan O, Rudomen G, Matzinger P. The role of dendritic cells, B cells, and M cells in gut-oriented immune responses. J Immunol. 2001;166: 4843-4852.
127. Targan SR, Deem RL, Liu M, et al. Definition of a lamina propria T cell responsive state. Enhanced cytokine responsiveness of T cells stimulated through the CD2 pathway. J Immunol. 1995;154:664-675.
128. Pirzer UC, Schurmann G, Post S, et al. Differential responsiveness to CD3-Ti vs. CD2-dependent activation of human intestinal T lymphocytes. Eur J Immunol. 1990;20:2339-2342.
129. Qiao L, Schurmann G, Betzler M, et al. Activation and signaling status of human lamina propria T lymphocytes. Gastroenterology. 1991;101: 1529-1536.
130. Gonsky R, Deem RL, Hughes CC, et al. Activation of the CD2 pathway in lamina propria T cells up-regulates functionally active AP-1 binding to the IL-2 promoter, resulting in messenger RNA transcription and IL-2 secretion. J Immunol. 1998;160:4914-4922.
131. Khoo UY, Proctor IE, Macpherson AJ. CD4+ T cell down-regulation in human intestinal mucosa: evidence for intestinal tolerance to luminal bacterial antigens. J Immunol. 1997;158:3626-3634.
132. Zeitz M, Schieferdecker HL, James SP, et al. Special functional features of T-lymphocyte subpopulations in the effector compartment of the intestinal mucosa and their relation to mucosal transformation. Digestion. 1990;46:280-289.
133. Schieferdecker HL, Ullrich R, Weiss-Breckwoldt AN, et al. The HML-1 antigen of intestinal lymphocytes is an activation antigen. J Immunol. 1990;144:2541-2549.
134. De Maria R, Fais S, Silvestri M, et al. Continuous in vivo activation and transient hyporesponsiveness to TcR/CD3 triggering of human gut lamina propria lymphocytes. Eur J Immunol. 1993;23:3104-3108.
135. Aruffo A, Hollenbaugh D. Therapeutic intervention with inhibitors of co-stimulatory pathways in autoimmune disease. Curr Opin Immunol. 2001;13:683-686.
136. Joseph NE, Fiocchi C, Levine AD. Crohn's disease and ulcerative colitis mucosal T cells are stimulated by intestinal epithelial cells: implications for immunosuppressive therapy. Surgery. 1997;122:809-816.
137. Wong VL, Levine AD. Regulation of intestinal immune tolerance and protection is mediated by signaling through the CD2 receptor on lamina propria T cells. Surg Forum. 1999;L:54-56.
138. Ebnet K, Kaldjian EP, Anderson AO, et al. Orchestrated information transfer underlying leukocyte endothelial interactions. Annu Rev Immunol. 1996;14:155-177.
139. Dustin ML, de Fougerolles AR. Reprogramming T cells: the role of extracellular matrix in coordination of T cell activation and migration. Curr Opin Immunol. 2001;13:286-290.
140. Krivacic KA, Levine AD. Extracellular matrix conditions T cells for adhesion to tissue interstitium. J Immunol. 2003;170:5034-5044.
141. Chen Y, Inobe J, Weiner HL. Inductive events in oral tolerance in the TCR transgenic adoptive transfer model. Cell Immunol. 1997;178: 62-68.
142. Thornton AM, Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998;188:287-296.
143. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med. 2000;192: 295-302.
144. Weiner HL. Oral tolerance. Proc Natl Acad Sci U S A. 1994;91:10762-10765.
145. Tsuji NM, Mizumachi K, Kurisaki J. Interleukin-10-secreting Peyer's patch cells are responsible for active suppression in low-dose oral tolerance. Immunology. 2001;103:458-464.
146. Jump RL, Levine AD. Murine Peyer's patches favor development of an IL-10-secreting, regulatory T cell population, J Immunol. 2002;168: 6113-6119.
147. Westermann J, Bode U. Distribution of activated T cells migrating through the body: a matter of life and death, Immunol Today. 1999;20: 302-306.
148. MacDonald TT, Monteleone G, Pender SL. Recent developments in the immunology of inflammatory bowel disease. Scand J Immunol. 2000; 51:2-9.
149. Chadwick VS, Anderson RP. The role of intestinal bacteria in etiology and maintenance of inflammatory bowel disease. In: Gibson GR, Macfarlane GT, eds. Human Colonic Bacteria: Role in Nutrition, Physiology, and Pathology. Boca Raton: CRC Press; 1995:227-256.
150. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
151. Fabia R. Ar'Rajab A, Johansson ML, et al. Impairment of bacterial flora in human ulcerative colitis and experimental colitis in the rat. Digestion. 1993;54:248-255.
152. Schultsz C, Van Den Berg FM, Ten Kate FW, et al. The intestinal mucus layer from patients with inflammatory bowel disease harbors high numbers of bacteria compared with controls. Gastroenterology. 1999;117: 1089-1097.
153. Sartor RB. The influence of normal microbial flora on the development of chronic mucosal inflammation. Res Immunol. 1997;148:567-576.
154. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 1991; 338:771-774.
155. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262-267.
156. Ruseler-van Embden JG, Schouten WR, van Lieshout LM. Pouchitis: result of microbial imbalance? Gut. 1994;35:658-664.
157. Robinson M. Medical therapy of inflammatory bowel disease for the 21st century. Eur J Surg Suppl. 1998:90-8.
158. Podolsky DK, Isselbacher KJ. Composition of human colonic mucin. Selective alteration in inflammatory bowel disease. J Clin Invest. 1983; 72:142-153.
159. Raouf A, Parker N, Ryder S, et al. Ion exchange chromatography of purified colonic glycoproteins in inflammatory bowel disease: absence of a selective subclass defect. Gut. 1991;32:1139-1145.
160. Ligumsky M, Karmeli F, Sharon P, et al. Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology. 1981; 81:444-449.
161. Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984;86: 453-460.
162. Sharon P, Ligumsky M, Rachmilewitz D, et al. Role of prostaglandins in ulcerative colitis, enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology. 1978;75:638-640.
163. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med. 1987;107: 513-516.
164. Reuter BK, Asfaha S, Buret A, et al. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cytclooxygenase-2. J Clin Invest. 1996;98:2076-2085.
165. Levine AD, Fiocchi C. Immunology of inflammatory bowel disease. Curr Opin Gastroenterol. 2000;16:306-309.
166. Rutgeerts PJ. Review article: efficacy of infliximab in Crohn's disease - induction and maintenance of remission. Aliment Pharmacol Ther. 1999;13(Suppl 4):9-15.
167. Rugtveit J, Brandtzaeg P, Halstensen TS, et al. Increased macrophage subsets in inflammatory bowel disease: apparent recruitment from peripheral blood monocytes. Gut. 1994;35:669-674.
168. Reinecker H-C, Podolsky DK. Human intestinal epithelial cells express functional cytokine receptors sharing the common gc chain of the interleukin 2 receptor. Proc Natl Acad Sci U S A. 1995;92:8353-8357.
169. Watanabe M, Ueno Y, Yajima T, et al. Interleukin-7 is produced by human intestinal epithelial cells and regulates the proliferation of intestinal mucosal lymphocytes. J Clin Invest. 1995;95:2945-2953.
170. Huang GT-J, Eckmann L, Savidge TC, et al. Infection of human intestinal epithelial cells with invasive bacteria upregulates apical intercellular adhesion molecule-1 (ICAM-1) expression and neutrophil adhesion. J Clin Invest. 1996;98:572-583.
171. Nakazawa A, Watanabe M, Kanai T, et al. Functional expression of costimulatory molecule CD86 on epithelial cells in the inflamed colonic mucosa. Gastroenterology. 1999;117:536-545.
172. Mayer L, Eisenhardt D. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with inflammatory bowel disease. J Clin Invest. 1990;86:1255-1260.
173. Baklien K, Brandtzaeg P. Comparative mapping of the local distribution of immunoglobulin-containing cells in ulcerative colitis and Crohn's disease. Clin Exp Immunol. 1975;22:197-209.
174. Deodhar SD, Michener WM, Farmer RG. A study of the immunologic aspects of chronic ulcerative colitis and transmural colitis. Am J Clin Pathol. 1969;51:591-597.
175. Chapman RW, Cottone M, Selby WS, et al. Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis. Gut. 1986;27:86-91.
176. Mayet WJ. Press AG, Hermann E, et al. Antibodies to cytoskeletal proteins in patients with Crohn's disease. Eur J Clin Invest. 1990;20:516-524.
177. Saxon A, Shanahan F, Landers C, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86:202-210.
178. Duerr RH, Targan SR, Landers CJ, et al. Neutrophil cytoplasmic antibodies: a link between sclerosing cholangitis and ulcerative colitis. Gastroenterology. 1991;100:1385-1391.
179. Vecchi M, Bianchi MB, Sinico RA, et al. Antibodies to neutrophil cytoplasm in Italian patients with ulcerative colitis: sensitivity, specificity and recognition of putative antigens. Digestion. 1994;55:34-39.
180. Sandborn WJ, Landers CJ, Tremaine WJ, et al. Antineutrophil cytoplasmic antibody correlates with chronic pouchitis after ileal pouch-anal anastomosis. Am J Gastroenterol. 1995;90:740-747.
181. Takahashi F, Das KM. Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-bound immunoglobulin G from idiopathic ulcerative colitis. J Clin Invest. 1985;76:311-318.
182. Das KM, Dasgupta A, Mandal A, et al. Autoimmunity to cytoskeletal protein tropomyosin. A clue to the pathogenetic mechanisms for ulcerative colitis. J Immunol. 1993;150:2487-2493.
183. Mizoguchi A, Mizoguchi E, Chiba C, et al. Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice. J Exp Med. 1996;184:707-715.
184. Pallone F, Fais S, Squarcia O, et al. Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. In vivo state of activation and in vitro response to stimulation as defined by the expression of early activation antigens. Gut. 1987;28:745-753.
185. Matsuura T, West GA, Klein JS, et al. Immune activation gene products are resistant to IL4 inhibitory activity in Crohn's disease (CD). Gastroenterology. 1993;104:A739.
186. Fiocchi C, Youngman KR, Farmer RG. Immunoregulatory function of human intestinal mucosal lymphoid cells: evidence for enhanced suppressor cell activity in inflammatory bowel disease. Gut. 1983;24:692-701.
187. Goodacre RL, Bienenstock J. Reduced suppressor cell activity in intestinal lymphocytes from patients with Crohn's disease. Gastroenterology. 1982;82:653-658.
188. Kugathasan S, Willis J, Dahms BB, et al. Intrinsic hyperreactivity of mucosal T cells to interleukin-2 in pediatric Crohn's disease. J Pediatr. 1998;133:675-681.
189. Kusugami K, Youngman KR, West GA, et al. intestinal immune reactivity to interleukin 2 differs among Crohn's disease, ulcerative colitis and control. Gastroenterology. 1989;97:1-9.
190. Ina K, Itoh J, Fukushima K, et al. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol. 1999;163:1081-1090.
191. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-1270.
192. Elson CO, Cong Y, Iqbal N, et al. Immuno-bacterial homeostasis in the gut: new insights into an old enigma. Semin Immunol. 2001;13:187-194.
193. Cong Y, Brandwein SL, McCabe RP, et al. CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med. 1998;187:855-864.
194. Fiocchi C, Battisto JR, Farmer RG. Studies on isolated gut mucosal lymphocytes in inflammatory bowel disease. Detection of activated T cells and enhanced proliferation to Staphylococcus aureus and lipopolysaccharides. Dig Dis Sci. 1981;26:728-736.
195. Fuller R. Probiotics in human medicine. Gut. 1991;32:439-442.
196. Kruis W, Schutz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853-858.
197. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635-639.
198. Madsen KL. The use of probiotics in gastrointestinal disease. Can J Gastroenterol. 2001;15:817-822.
199. Gionchetti P, Rizzello F, Venturi A, et al. Probiotics in infective diarrhoea and inflammatory bowel diseases, J Gastroenterol Hepatol. 2000; 15:489-493.
200. Robinson JK, Blanchard TG, Levine AD, et al. A mucosal IgA-mediated excretory immune system in vivo. J Immunol. 2001;166:3688-3692.
201. Read S, Mauze S, Asseman C, et al. CD38+ CD45RB(low) CD4+ T cells: a population of T cells with immune regulatory activities in vitro. Eur J Immunol. 1998;28:3435-3447.
202. Asseman C, Mauze S, Leach MW, et al. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;190:995-1004.